X4 PHARMACEUTICALS, INC (XFOR) Return on equity 2019–2025
X4 PHARMACEUTICALS, INC (XFOR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-42.5%FY2025 · since FY2019: -40.9% → -42.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -42.5% | +126.6 pp |
| FY2024 | -169.1% | +28.9 pp |
| FY2023 | -198.0% | -71.2 pp |
| FY2022 | -126.8% | +10.9 pp |
| FY2021 | -137.7% | -52.4 pp |
| FY2020 | -85.3% | -44.5 pp |
| FY2019 | -40.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More XFOR financial trends
XFOR RevenueXFOR Net incomeXFOR Net marginXFOR Gross profitXFOR Gross marginXFOR Operating incomeXFOR Operating marginXFOR Operating cash flowXFOR Free cash flowXFOR Capital expendituresXFOR Stock buybacksXFOR Dividends paidXFOR Total assetsXFOR Total liabilitiesXFOR Shareholders’ equityXFOR overview →